Pharmaceuticals

Tumor Infiltrating Lymphocytes Market Anticipated to Record Steady Gains, Advancing to $23.25 Billion by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the tumor infiltrating lymphocytes market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Tumor Infiltrating Lymphocytes Market between 2026 and 2030?

The tumor infiltrating lymphocytes market size has experienced rapid expansion in recent years. Projections indicate that this market will expand from $12.05 billion in 2025 to reach $13.75 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. Historically, this growth has been fueled by factors such as the increasing prevalence of cancer, significant advancements in immunotherapy research, a growing awareness regarding personalized medicine, the initial successes observed with adoptive cell therapies, and enhanced collaborations between research institutes and biotechnology companies.

The market size for tumor infiltrating lymphocytes is anticipated to undergo substantial growth in the coming years. It is projected to expand to $23.25 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.0%. This growth during the forecast period is primarily driven by the increasing adoption of tumor infiltrating lymphocytes therapies, the expansion of cGMP-compliant manufacturing facilities, the integration of AI in optimizing cell therapy processes, a surge in strategic alliances between pharmaceutical and biotech firms, and regulatory green lights for innovative T-cell therapies. Noteworthy trends expected in the forecast period include the advancement of personalized cell therapy, developments in ex vivo T-cell expansion techniques, the emergence of immunotherapy combination strategies, modulation of the tumor microenvironment, and sophisticated approaches to cell storage and cryopreservation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9440&type=smp

Which Drivers Are Expected To Impact The Tumor Infiltrating Lymphocytes Market During The Forecast Period?

The increasing incidence of cancer is anticipated to fuel the expansion of the tumor infiltrated lymphocytes (TIL) market moving ahead. Cancer, a disease where body cells grow uncontrollably and disseminate, often causes severe, sometimes deadly, health problems. Tumor-infiltrating lymphocytes are immune cells capable of identifying and eliminating cancer cells. These lymphocytes are isolated from a patient’s tumor, massively expanded in vitro in a lab, and then re-infused into the patient to bolster the immune system’s fight against cancer cells. For example, an August 2024 report from the Australian Institute of Health and Welfare, Australia’s national health and welfare data agency, forecasted that by 2034, Australia will likely see around 209,000 new cancer diagnoses. This represents a substantial rise from the approximately 169,000 cases predicted for 2024, attributed to population growth and increasing cancer prevalence. Furthermore, in 2024, cancer is expected to be responsible for roughly 3 out of every 10 deaths within the nation. Consequently, the growing number of cancer patients will propel demand in the tumor infiltrated lymphocytes (TIL) market.

How Is The Tumor Infiltrating Lymphocytes Market Divided Into Segments?

The tumor infiltrating lymphocytes market covered in this report is segmented –

1) By Anatomy: CD3, CD8, CD16, CD56, CD4, CD57, FOXP3

2) By Component: T-Cells, Natural Killer Cells

3) By Application: Melanoma, Cervical Cancer, Ovarian Cancer, Other Applications

4) By End-User: Hospitals, Cancer Research Centers, Clinics

Which Trends Are Guiding The Evolution Of The Tumor Infiltrating Lymphocytes Market?

Leading firms within the tumor-infiltrating lymphocyte market are increasingly engaging in strategic alliances, with the goal of creating pioneering treatments capable of managing gene editing. Such alliances involve businesses combining their respective strengths and assets to attain shared advantages and favorable outcomes. As an illustration, during February 2023, Moderna, a pharmaceutical and biotechnology company based in the US, formed a strategic collaboration with Life Edit Therapeutics, a US-based company specializing in next-generation genome editing, to expedite the progress of new in vivo gene editing therapies. The objective of this joint effort is to utilize Moderna’s mRNA technology in conjunction with Life Edit’s unique genome editing platform, thereby developing more efficacious and accurate treatments for a range of conditions, such as cancer and genetic ailments. This particular collaboration underscores a burgeoning inclination within the biopharmaceutical sector to merge innovative technologies for the development of sophisticated therapeutic remedies.

Which Major Firms Are Strengthening Their Position In The Tumor Infiltrating Lymphocytes Market?

Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Tumor Infiltrating Lymphocytes Market?

North America was the largest region in the tumor infiltrating lymphocytes market in 2025. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tumor Infiltrating Lymphocytes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9440&type=smp

Browse Through More Reports Similar to the Global Tumor Infiltrating Lymphocytes Market 2026, By The Business Research Company

Tumor Infiltrating Lymphocytes Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Circulating Tumor Cells Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795